StockWatch
·
Q1 FY-2027 RESULTS · NITTAGELA

Nitta Gelatin PAT +32% YoY to ₹25.2 Cr on cost relief; revenue flat, -13% QoQ

PAT +31.63% YoY · revenue +1.5% · margins expanding

Q1 FY27 resultsNITTAGELANITTA GELATIN INDIA LTD.-$31 Jul 2026 · 3 min read
Revenue

₹140.87 Cr

+1.5% YoY

PAT (consolidated)

₹25.18 Cr

+31.63% YoY

Net margin

17.42%

+3.9pp YoY

EPS

₹27.73

Nitta Gelatin India's consolidated net profit rose 31.6% year-on-year to ₹25.18 Cr in Q1 FY27 (quarter ended 30 June 2026), even as revenue from operations grew just 1.5% YoY to ₹140.87 Cr — making this a margin-led print rather than a volume or pricing story. The operating (EBITDA) margin expanded roughly 466 bps to 24.46% from 19.80% a year ago, and net profit margin rose to 17.42% from 13.54%, as net material cost (cost of materials consumed, adjusted for the inventory-build credit) eased to about 42.1% of revenue from 46.6% in the year-ago quarter — consistent with management's own note that the business's performance is dependent on raw-material quality, availability and price. There were no exceptional items in either this quarter or the year-ago comparator, so the 31.6% YoY PAT growth is a clean, unadjusted number. Standalone PAT of ₹25.19 Cr is nearly identical to the consolidated figure, confirming the small Bamni Proteins subsidiary carries negligible weight on the group result.

The scoreboard

Q1 FY-2027 vs prior quarters

Consolidated P&L, ₹ Crore
Q1 FY-2027QoQYoY
Revenue₹140.87 Cr-12.9%+1.5%
Expenses₹110.56 Cr-8.1%-3.9%
PAT₹25.18 Cr-26.15%+31.63%
Net margin17.42%-3pp+3.9pp
EPS₹27.73-26.2%+28.1%

Sequentially, the picture is softer: revenue fell 12.9% QoQ from Q4 FY26's ₹161.73 Cr and PAT fell 26.2% QoQ from ₹34.09 Cr, with OPM down from 28.06% and NPM down from 20.46%. This looks like a seasonal step-down and mild operating deleverage rather than a fresh cost problem — employee expense rose to 9.65% of revenue (from 7.82% in Q4) and other expenses to 23.80% (from 21.66%) as a broadly fixed cost base sat over a smaller Q1 revenue base, while the net-material-cost ratio itself was little changed QoQ (42.1% vs 42.5%). There is no management guidance or prior concall commentary on record to grade this print against, and no analyst/street coverage was found for this small-cap name, so both vsGuidance and vsStreet are unknown. The remaining quarter-relevant disclosures are governance/legal rather than financial: the board used the same meeting to approve a postal ballot for a KSIDC nominee-director change; Bamni Proteins (shut since a March 2024 Maharashtra Pollution Control Board closure order) stays classified as a discontinued operation with a marginal ₹0.10 Cr loss this quarter while the board explores disposing of its assets on a non-going-concern basis; and the company continues to carry an ₹18.20 Cr contingent liability on a customs-duty/fish-protein import-classification dispute now before the Supreme Court (interim stay granted, final hearing slated for September 2026), with no P&L impact this quarter.

811.081,149.291,487.51,825.712,163.921,90904-2705-2006-1507-0907-31Q1 FY-2027 results
The tape into the print — daily closes, last 3 months

The stock went into the print at ₹1,909, up 13% over the past month of trading.

₹ Cr
012.7325.4538.1819.69Q4 FY25rev ₹129 Cr19.13Q1 FY26rev ₹139 Cr18.38Q2 FY26rev ₹138 Cr25.59Q3 FY26rev ₹150 Cr34.09Q4 FY26rev ₹162 Cr25.18Q1 FY27rev ₹141 Cr
Quarterly consolidated PAT, ₹ Crore
  • W1

    Whether the net material cost ratio (~42.1% of revenue this quarter, down from ~46.6% YoY) holds or reverses — this quarter's PAT growth is entirely margin-led, not volume-led

  • W2

    Resolution timeline for the Bamni Proteins subsidiary — board is exploring asset disposal; any sale, further write-down or restart decision would move consolidated numbers

  • W3

    Supreme Court hearing (scheduled September 2026) on the ₹18.20 Cr customs duty contingent liability

Informational and educational content only. Not investment advice.